NEWS
Cortex Announces $1.5 Million Private Placement
Cortex Receives Delisting Notification from NYSE Amex
Cortex Reports Third Quarter Operating Results
Cortex’s CEO to Present at Rodman & Renshaw’s Eleventh Annual Healthcare Conference on September 10, 2009
Cortex Reports Second Quarter Operating Results
Cortex Pharmaceuticals Announces Financing
Cortex Annual Shareholder Meeting Notification
Cortex Receives Notice of Non-Compliance From NYSE Amex For Continued Listing Requirements
Cortex Reports First Quarter Operating Results
Cortex Announces Closing of Financing
Cortex Announces Financing
Cortex Reports Fourth Quarter and Year End Operating Results
Cortex Pharmaceuticals Announces Corporate Restructuring and Workforce Reduction
Studies in Animals Demonstrate AMPAKINE Molecules Reverse Memory Loss in Huntington’s Disease
Cortex’s CEO to Present at the Roth Capital Partners 21st Annual Orange County Growth Stock Conference
Cortex Receives UK Regulatory Approval to Initiate a Clinical Study in Sleep Apnea with its AMPAKINE CX1739
Cortex Reports Third Quarter Operating Results
Cortex’s CEO to Present at Rodman & Renshaw’s Tenth Annual Healthcare Conference on November 10, 2008
Cortex’s AMPAKINE® Research in Opioid–Induced Respiratory Depression makes Windhover’s Top 10 List of Neuroscience Projects Available for Partnering
Cortex’s AMPAKINE Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany
Cortex Reports Second Quarter Operating Results
Cortex’s AMPAKINE Molecule CX717 Has Positive Effects in Opiate–Induced Respiratory Depression in a Phase IIa Clinical Study
Cortex to Provide Top Line Data for CX717 Clinical Trial for the Prevention of Opiate-Induced Respiratory Depression in Humans
CORTEX and Top Alberta Government officials meet to Discuss progress on AMPAKINE Compounds AT The 2008 Bio Conference
Alberta pharmaceutical industry expands international partnerships
Cortex Pharmaceuticals Announces Management Changes
Cortex Annual Shareholder Meeting Notification
Cortex Reports First Quarter Operating Results
Cortex Initiates Enrollment in Opiate Induced Respiratory Depression Clinical Trial in Germany Today
Cortex Reports Fourth Quarter and Year End Operating Results
Cortex Receives Approval from German Regulatory Authority to Proceed With two Clinical Trials for AMPAKINE® CX717 for the Acute Treatment of Respiratory Depression due to Opiate Analgesics
Cortex’s CEO to Present at the Roth Capital Partners 20th Annual Orange County Conference
Cortex’s CEO Roger Stoll to Speak at the Bank of Montreal’s Focus on Healthcare Conference
Cortex Reports Third Quarter Operating Results
Cortex’s CEO to Present at Rodman & Renshaw’s Ninth Annual Healthcare Conference On November 5, 2007
Cortex to Provide Shareholder Update and Host Conference Call on October 31, 2007
Cortex Names Pierre V. Trân, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
FDA’s Psychiatric Division has Rejected Cortex’s Request to Study CX717 in Phase IIb ADHD Study
Cortex to Provide Shareholder Update and Host Conference Call on September 19, 2007
Cortex Files Ampakine CX717 IND for ADHD
Cortex’s CEO Roger Stoll to Speak at the Bear Stearns 20th Annual Healthcare Conference, New York, on September 10th, 2007
Cortex’s CEO Roger Stoll to Speak at the Roth Capital Partners New York Conference on September 5, 2007
Cortex Completes $14.2 Million Registered Direct Offering
Cortex to Raise $14.2 Million in Registered Direct Offering
Cortex Reports Second Quarter Operating Results
Cortex to Resume Clinical Trial with AMPAKINE® CX717 in Alzheimer-PET Scan Study After FDA Approves Protocol with Higher Doses of Drug
Cortex and the University of California, Irvine Extend Exclusive Licensing Agreement
Cortex's CEO to Present at the JMP Securities Research Conference and Cortex's COO to Present at the Neurotech Industry Investing & Partnering Conference
Cortex and The University of Alberta complete patent license agreement
Cortex Reports First Quarter Operating Results
Cortex Annual Shareholder Meeting Notification
Cortex’s AMPAKINE CX717 Toxicology Data Package Submitted To FDA
Cortex Reports Fourth Quarter and Year End Operating Results
Cortex has licensed its AMPAKINE technology to Organon BioSciences N.V. Schering-Plough Corporation will acquire Organon BioSciences.
Cortex Pharmaceuticals Appoints Les Street, Ph.D., Head of Medicinal Chemistry and Steven A. Johnson, Ph.D., VP of Pre-Clinical Development Becomes an Officer of Cortex
Update On Cortex’s CEO Presentation At The Roth Capital Partners 19th Annual Conference
Cortex’s CEO To Present At The Roth Capital Partners 19th Annual Orange County Conference
Cortex Completes $5.6 Million Direct Equity Placement
Cortex To Raise $5.6 Million in Direct Equity Placement
|